• 400+
    Pharmaceutical Partners
  • 150+
    Biomarker Assays
  • 300+
    Method Validations
  • 40+
    CDx

Clinical Testing

Patient Testing for Precision Medicine

  • Pan solid tumor
    Meet the diverse demands from clinicians and patients, MEDx Translational Medicine (MEDx) has developed a series of solid tumor tests, including pan-cancer gene panel tests, single cancer gene panel assays, and immunohistochemistry (IHC).
  • Hematologic Malignancy
    Most recently, molecular diagnostic products using PCR and next-generation sequencing (NGS) have significantly improved the understanding of molecular mechanism of hematological malignancies, leading to the right choice of molecular targeting drugs for precision therapy for the individual patients in clinic.
  • Infectious Disease
    Infectious Disease

About MEDx

Translational Medicine

MEDx Translational Medicine Co., Ltd (simply MEDx) was founded in 2013, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd.Obtained with comprehensive technology platforms, high quality system, and strong IVD R&D experience, MEDx has become a leading innovative company in companion diagnostics and the total solution provider for precision medicine in China.


Taking advantage of the comprehensive translational platforms including genomics, proteomics, cytomics, and pathology, MEDx offers integrated solutions from biomarker discovery, target validation, molecular testing, and patient  stratification for drug clinical trials, to the IVD/CDx R&D and commercialization. With a world-class technical team and a rich IVD/CDx pipeline, MEDx collaborates with hundreds of world-renowned pharmaceutical companies.

view more >>

Events

Happy Chinese New Year
MEDx TMC | Happy Mid-Autumn Festival
MEDx Invite You: Medlab Asia & Asia Health on July 10th-12th, 2024

We are honored to invite you to participate in the Medlab Asia & Asia Health, which will take

MEDx TMC | Happy Father’s Day!
Dragon Boat Festival
Welcome to visit the MEDx Booth at Medlab Middle East 2024

Time:5-8 February, 2024Address:Dubai World Trade CentreMEDx Booth No: # Z2.H19We are honored

Meet MEDx at Medlab Middle East | Dubai 2024
On series |PIK3CA gene mutation and targeted therapy

Introduction The study of cancer has been extended from single genes to macrogenes, and from sing

GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Class Failures

Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cance

Kura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With Syndax

Kura Oncology won FDA priority review for its drug the day before announcing new data at ASCO 2025 s

Roche and Jazz Link Drug Combo to Improved Survival in Phase III Lung Cancer Trial

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for th

Bladder cancer treatment reprograms bone marrow to boost immune system's cancer-fighting ability

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-

Potent CDK9 inhibitor shows promise for overcoming drug resistance in hematological malignancies

A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9

Personalized cancer model predicts patient-specific gene behavior, potentially improving survival ou

Carnegie Mellon University researchers are using personalized models to decode how cancer behaves in

Study sheds light on enzyme's role in driving lymphoma growth

A study led by University of Cincinnati Cancer Center researchers sheds new light on the mechanisms

Novel biomarker has potential for predicting and treating skin cancer metastasis

Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in pat